Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIGNAL - Body Fluid Proteome SIGnatures for persoNALised Intervention to Prevent Cardiovascular and Renal Complications in Diabetes
NCT06954090Phase 4Enrolling by invitation
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide, finerenone, dapagliflozin in type 2 diabetes mellitus (T2DM), diabetic nephropathy (DN), albuminuria, sponsored by Steno Diabetes Center Copenhagen. Started Nov 2025; status: enrolling by invitation.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic nephropathy (DN)albuminuria
Beyond the preview
Go deeper on NCT06954090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06954090.